Precision Medicine Clinic: Molecular Tumor Board
Precision Medicine Clinic: Molecular Tumor Board is a case-based series designed to help clinicians optimize molecular testing for their patients. The Editors of The Oncologist encourage institutions to share their findings and experiences to help improve the precision of genomic oncology and fulfill its promise of improved outcomes for patients. This collection highlights a diverse set of patients exhibiting a range of tumor types and mutations. We hope you find the clinical outcomes beneficial in your practice.
Understanding the Precision in “Precision Medicine”
Bruce A. Chabner
The Oncologist 2016; 21:1029-1030; first published on August 26, 2016;doi:10.1634/theoncologist.2016-0278
Search by Type:
ALK | BRCA | EGFR | ERBB2 | ESR1 | IDH | KRAS | MET | POLE | SMAD4 | SMARCB1 | TMB | Immunotherapy | Germline mutations/Hereditary syndromes
ALK
The Oncologist first published on January 24, 2019; doi:10.1634/theoncologist.2018-0439
The Oncologist first published on May 8, 2018; doi:10.1634/theoncologist.2018-0014
The Oncologist 2017; 22:768-773; first published on May 15, 2017; doi:10.1634/theoncologist.2017-0054
The Oncologist 2017; 22:774-779; first published on May 15, 2017; doi:10.1634/theoncologist.2016-0376
BRCA
The Oncologist first published on November 1, 2019; doi:10.1634/theoncologist.2019-0393
The Oncologist first published on April 5, 2018; doi:10.1634/theoncologist.2017-0645
The Oncologist first published on February 22, 2018; doi:10.1634/theoncologist.2017-0526
EGFR
The Oncologist first published on October 22, 2019; doi:10.1634/theoncologist.2019-0405
The Oncologist first published on May 7, 2019; doi:10.1634/theoncologist.2018-0732
The Oncologist first published on April 25, 2019; doi:10.1634/theoncologist.2019-0101
The Oncologist first published on January 2, 2019; doi:10.1634/theoncologist.2018-0387
ERBB2
The Oncologist 2018; 23:150-154; first published on November 16, 2017; doi:10.1634/theoncologist.2017-0345
ESR1
The Oncologist 2016; 21:1035-1040; first published on August 22, 2016; doi:10.1634/theoncologist.2016-0240
IDH
The Oncologist first published on October 23, 2018; doi:10.1634/theoncologist.2018-0210
KRAS
The Oncologist first published on September 6, 2018; doi:10.1634/theoncologist.2018-0295
MET
The Oncologist first published on August 7, 2019; doi:10.1634/theoncologist.2019-0230
POLE
The Oncologist 2017; 22:497-502; first published on May 2, 2017; doi:10.1634/theoncologist.2017-0034
SMAD4
The Oncologist first published on November 9, 2018; doi:10.1634/theoncologist.2018-0016
SMARCB1
The Oncologist first published on October 8, 2018; doi:10.1634/theoncologist.2018-0279
TMB
The Oncologist first published on January 31, 2018; doi:10.1634/theoncologist.2017-0342
The Oncologist 2017; 22:631-637; first published on May 26, 2017; doi:10.1634/theoncologist.2016-0517
Immunotherapy
The Oncologist first published on December 17, 2019; doi:10.1634/theoncologist.2019-0739
The Oncologist first published on December 12, 2018; doi:10.1634/theoncologist.2018-0546
The Oncologist first published on October 24, 2018; doi:10.1634/theoncologist.2018-0434
The Oncologist first published on August 13, 2018; doi:10.1634/theoncologist.2018-0163
The Oncologist 2017; 22:1149-1151; first published on August 4, 2017; doi:10.1634/theoncologist.2017-0096
The Oncologist first published on August 2, 2018; doi:10.1634/theoncologist.2018-0108
Germline mutations/Hereditary syndromes
The Oncologist first published on February 26, 2020; doi:10.1634/theoncologist.2019-0563
The Oncologist first published on August 23, 2019; doi:10.1634/theoncologist.2018-0686
The Oncologist first published on January 25, 2019; doi:10.1634/theoncologist.2018-0614
The Oncologist first published on June 4, 2018; doi:10.1634/theoncologist.2017-0681
The Oncologist first published on February 14, 2018; doi:10.1634/theoncologist.2017-0372
Back to Top